Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fluorine F 18 fluorothymidine
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
Fluorothymidine F 18-Labeled Positron Emission Tomography in Finding Recurrent Disease in Patients With Primary Brain Tumors
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: HCI20112, NCI-2010-00958, NCT00707343
Axitinib in Treating Patients with Melanoma That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 197811, NCI-2011-03037, NCT01533948
FLT PET/CT in Planning Pelvic Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201204712, NCI-2013-00956, 04120117, NCT01717391
18F-FLT PET Imaging in Assessing Tumors and Measuring Response in Younger Patients With Brain Tumors
Phase: Phase II
Type: Diagnostic
Age: 21 and under
Trial IDs: PBTC-N12, NCI-2013-00805, NCT01244737
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients with Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: UW13112, NCI-2014-00944, NCT02146222
Multi-tracer PET in Imaging Patients with Brain Tumors
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: HCI31335, NCI-2014-01824, 31335, NCT00813566
Positron Emission Tomography-Computed Tomography in Monitoring Treatment in Patients with Diffuse Large B-Cell Lymphoma Receiving First-Line Therapy
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: LYMIMG0001, NCI-2012-02178, NCT01410630
Fluorothymidine-Labeled Positron Emission Tomography in Measuring Response in Patients With Previously Untreated Intermediate- or High-Risk Myelodysplastic Syndrome Receiving Azacitidine
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: HO10417, NCI-2012-00362, 2011-0285, 2011-0285-CP005, NCT01535456
MRI in Measuring Biomarkers of Early Treatment Response in Patients With Osteosarcoma or Ewing Sarcoma
Phase: No phase specified
Type: Diagnostic
Age: 13 and over
Trial IDs: VICC SAR 1275, NCI-2013-01359, NCT01882231
FLT PET in Measuring Treatment Response in Patients with Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 18 and over
Trial IDs: 7536, NCI-2013-01380, NCT01928186
FLT-PET/MRI in Measuring Early Response in Patients with Metastatic Solid Tumors Receiving Treatment That Blocks Blood Flow to the Tumor
Phase: No phase specified
Type: Diagnostic
Age: 18 and older
Trial IDs: CASE 3Y12, NCI-2013-01177, NCT02055586
18F-FLT PET/CT in Sparing Bone Marrow in Patients With Gynecologic Cancer Undergoing Radiation Therapy
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: UPCC 28813, NCI-2014-00861, 819177, NCT02108457
18F-FLT PET/CT in Measuring Cell Proliferation in Patients with Brain Tumors
Phase: No phase specified
Type: Diagnostic
Age: 18 and over
Trial IDs: 7754, NCI-2013-02162, NCT02167204
FLT PET in Predicting Malignant Tumors in Patients with Neurofibromatosis Type I
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 10 and over
Trial IDs: 14-C-0163, NCI-2014-02502, P141559, NCT02211768
Start Over